Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulator Sensitivity and Resistance in Multiple Myeloma
NCT05288062Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2022
- Primary completion
- Feb 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, pomalidomide in multiple myeloma (MM), smoldering multiple myeloma (SMM), sponsored by Mayo Clinic. Started Jun 2022; status: terminated.
02
Drugs
lenalidomidepomalidomide
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05288062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288062.